Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have earned an average recommendation of “Moderate Buy” from the twenty-one brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, nine have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $36.6316.

A number of equities research analysts have recently weighed in on the stock. The Goldman Sachs Group reduced their price target on shares of Ultragenyx Pharmaceutical from $28.00 to $19.00 and set a “neutral” rating on the stock in a research note on Friday. Wall Street Zen upgraded shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. HC Wainwright dropped their price objective on shares of Ultragenyx Pharmaceutical from $50.00 to $25.00 and set a “buy” rating for the company in a research note on Thursday, September 3rd. Canaccord Genuity Group cut their target price on shares of Ultragenyx Pharmaceutical from $83.00 to $37.00 and set a “buy” rating on the stock in a research report on Thursday, September 3rd. Finally, Royal Bank Of Canada cut shares of Ultragenyx Pharmaceutical from a “moderate buy” rating to a “hold” rating in a research note on Thursday, September 3rd.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, EVP Karah Parschauer sold 1,899 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $24.62, for a total value of $46,753.38. Following the completion of the transaction, the executive vice president owned 94,462 shares of the company’s stock, valued at $2,325,654.44. This represents a 1.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Corsee Sanders sold 2,000 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $25.05, for a total value of $50,100.00. Following the completion of the transaction, the director owned 21,095 shares of the company’s stock, valued at $528,429.75. This represents a 8.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Large investors have recently modified their holdings of the business. Parallel Advisors LLC increased its stake in shares of Ultragenyx Pharmaceutical by 778.4% in the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 1,440 shares during the period. Leonteq Securities AG boosted its holdings in Ultragenyx Pharmaceutical by 288.5% in the first quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 1,333 shares during the last quarter. Versant Capital Management Inc boosted its holdings in Ultragenyx Pharmaceutical by 662.9% in the second quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 1,001 shares during the last quarter. Danske Bank A S acquired a new stake in Ultragenyx Pharmaceutical during the 3rd quarter valued at approximately $39,000. Finally, EverSource Wealth Advisors LLC increased its position in Ultragenyx Pharmaceutical by 573.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 1,845 shares during the period. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE opened at $15.30 on Tuesday. Ultragenyx Pharmaceutical has a 52-week low of $13.81 and a 52-week high of $39.89. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -2.62 and a beta of 0.31. The business’s fifty day moving average is $27.46 and its 200-day moving average is $24.97.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The business had revenue of $214.00 million for the quarter, compared to analyst estimates of $183.08 million. During the same period last year, the firm posted ($1.17) earnings per share. Ultragenyx Pharmaceutical’s revenue was up 28.5% compared to the same quarter last year. As a group, research analysts forecast that Ultragenyx Pharmaceutical will post -3.98 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.